Limits...
TRIM29 as a novel biomarker in pancreatic adenocarcinoma.

Sun H, Dai X, Han B - Dis. Markers (2014)

Bottom Line: TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019).Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression.Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Biliary and Vascular Surgery, Shengjing Hospital of China Medical University, Heping District, Shenyang 110004, China.

ABSTRACT

Background and aim: Tripartite motif-containing 29 (TRIM29) is structurally a member of the tripartite motif family of proteins and is involved in diverse human cancers. However, its role in pancreatic cancer remains unclear.

Methods: The expression pattern of TRIM29 in pancreatic ductal adenocarcinoma was assessed by immunocytochemistry. Multivariate logistic regression analysis was used to investigate the association between TRIM29 and clinical characteristics. In vitro analyses by scratch wound healing assay and invasion assays were performed using the pancreatic cancer cell lines.

Results: Immunohistochemical analysis showed TRIM29 expression in pancreatic cancer tissues was significantly higher  (n = 186) than that in matched adjacent nontumor tissues. TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019). Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression. Multivariate analysis revealed that TRIM29 was an independent factor for pancreatic cancer over survival (HR = 2.180, 95% CI: 1.324-4.198, P = 0.011). In vitro, TRIM29 knockdown resulted in inhibition of pancreatic cancer cell proliferation, migration, and invasion.

Conclusions: Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier curves of (a) overall survival and (b) recurrence-free survival in 186 patients with pancreatic cancer according to TRIM29-negative or TRIM29-positive expression status.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016900&req=5

fig2: Kaplan-Meier curves of (a) overall survival and (b) recurrence-free survival in 186 patients with pancreatic cancer according to TRIM29-negative or TRIM29-positive expression status.

Mentions: The median follow-up period for overall survival was 19.2 months (range of 0.5–60 months). By univariate analysis using the log-rank test, there was a statistically significant difference in the 5-year survival between TRIM29-positive and TRIM29-negative tumors (TRIM29-positive tumor: median overall survival of 16.4 months, TRIM29-negative tumor: median overall survival of 32.3 months, P < 0.001, Figure 2(a)). Additionally, the patients with TRIM29-positive tumors showed significantly reduced recurrence-free survival compared to patients with TRIM29-negative tumors (TRIM29-positive tumor: recurrence-free survival of 10.8 months, TRIM29-negative tumor: recurrence-free survival of 17.1 months, P = 0.008, Figure 2(b)). During this period, 156 patients experienced metastatic recurrence and died of pancreatic cancer directly and 25 died of noncancer causes, such as side effects from treatment.


TRIM29 as a novel biomarker in pancreatic adenocarcinoma.

Sun H, Dai X, Han B - Dis. Markers (2014)

Kaplan-Meier curves of (a) overall survival and (b) recurrence-free survival in 186 patients with pancreatic cancer according to TRIM29-negative or TRIM29-positive expression status.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016900&req=5

fig2: Kaplan-Meier curves of (a) overall survival and (b) recurrence-free survival in 186 patients with pancreatic cancer according to TRIM29-negative or TRIM29-positive expression status.
Mentions: The median follow-up period for overall survival was 19.2 months (range of 0.5–60 months). By univariate analysis using the log-rank test, there was a statistically significant difference in the 5-year survival between TRIM29-positive and TRIM29-negative tumors (TRIM29-positive tumor: median overall survival of 16.4 months, TRIM29-negative tumor: median overall survival of 32.3 months, P < 0.001, Figure 2(a)). Additionally, the patients with TRIM29-positive tumors showed significantly reduced recurrence-free survival compared to patients with TRIM29-negative tumors (TRIM29-positive tumor: recurrence-free survival of 10.8 months, TRIM29-negative tumor: recurrence-free survival of 17.1 months, P = 0.008, Figure 2(b)). During this period, 156 patients experienced metastatic recurrence and died of pancreatic cancer directly and 25 died of noncancer causes, such as side effects from treatment.

Bottom Line: TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019).Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression.Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Biliary and Vascular Surgery, Shengjing Hospital of China Medical University, Heping District, Shenyang 110004, China.

ABSTRACT

Background and aim: Tripartite motif-containing 29 (TRIM29) is structurally a member of the tripartite motif family of proteins and is involved in diverse human cancers. However, its role in pancreatic cancer remains unclear.

Methods: The expression pattern of TRIM29 in pancreatic ductal adenocarcinoma was assessed by immunocytochemistry. Multivariate logistic regression analysis was used to investigate the association between TRIM29 and clinical characteristics. In vitro analyses by scratch wound healing assay and invasion assays were performed using the pancreatic cancer cell lines.

Results: Immunohistochemical analysis showed TRIM29 expression in pancreatic cancer tissues was significantly higher  (n = 186) than that in matched adjacent nontumor tissues. TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019). Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression. Multivariate analysis revealed that TRIM29 was an independent factor for pancreatic cancer over survival (HR = 2.180, 95% CI: 1.324-4.198, P = 0.011). In vitro, TRIM29 knockdown resulted in inhibition of pancreatic cancer cell proliferation, migration, and invasion.

Conclusions: Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

Show MeSH
Related in: MedlinePlus